248. Coelho D., Suormala T., Stucki M. et al. Gene identification for the cblD defect of vitamin B12 metabolism // N Engl J Med. – 2008. – V. 358. – № 14. – P. 1454–1464.
249. Consoli D., Di Carlo A., Inzitari D. et al. Subcortical ischaemic changes in young hypertensive patients: frequency, effect on cognitive performance and relationship with markers of endothelial and haemostatic activation // Eur J Neurol. – 2007. – V. 14. – № 11. – P. 222–1229.
250. Craiq D., Birks J. Galantamine for vascular cognitive impairment // Cochrane Database Syst Rev. – 2006. – V. 25. – № 1. – CD004746.
251. Cummings J. L., Mackell J., Kaufer D. Behavioral effects of current Alzheimers disease treatments // Alzheimers dementia. – 2008. – V. 4. – № 1. – P. 49–60.
252. Davison A. N., Dobbing J. Applied Neurochemistry. – Philadelphia: Davis, 1968. – 342 p.
253. Dubois B., Stachevsky A., Litvan I., Pillon B. The FAB: a frontal assessement battery at bedside // Neurology. – 2000. – V. 55 – № 5. – P. 1621–1626.
254. Dubois B., Feldman H. H., Jacova C. et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria // Lancet Neurol. – 2007. – V. 6. – № 8. – P. 734–746.
255. Duff K., Mold J., Roberts MM. Walking speed and global cognition: results from the OKLAHOMA study // Neuropsychol Dev. Cogn. B. Aging. Neuropsychol. Cogn. – 2007. – V. 18. – № 1. – P. 1–9.
256. Duran E., Chacon J. R. Parkinsonism probably induced by manganese // Rev Neurol. – 2001. – Vol. 33. – № 5. – P. 434–436.
257. Durga J., van Boxtel M. P., Schouten E. G. et al. Effect of 3-year folic acid supplementation on cognitive function in older adults // Lancet. – 2007. – V. 369. – P. 208–216.
258. Echeverria D., Woods J. S., Heyer N. J. et al. The association between a genetic polymorphism of coproporphyrinogen oxidase, dental mercury exposure and neurobehavioral response in humans // Neurotoxicol Teratol. – 2006. – V. 28. – № 1. – P. 39–48.
259. Eichenwald E. C., Stark A. R. Management and outcomes of very low birth weight // N Engl J Med. – 2008. – V. 358. – № 16. – P. 1700–1711.
260. Eide P. K. Intracranial pressure parameters in INPH patients treated with ventriculo-peritoneal shunts // Acta Neurochir (Wien). – 2006. – V. 148. – № 1. – P. 21–29.
261. Emre M., Aarsland D., Albanese A. Rivastigmine for dementia associated with Parkinsons disease // N. Engl. J. Med. – 2004. – V. 351. – № 24. – P. 2509–2518.
262. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis // Neurology. – 2002. – V. 59. – № 5. – P. 674–678.
263. Fielding J., Georgiou-Karistianis N., White O. The role of the basal ganglia in the control of automatic visuospatial attention // J. Int.Neuropsychol Soc. – 2006. – V. 12. – № 5. – P. 657–667.
264. Fiszer U. Does Parkinson’s disease have an immunological basis? The evidence and its therapeutic implications // BioDrugs.-2001. – V. 15. – № 6. – P. 351–355.
265. Folstein M., Folstein S. Mc Hugh R. Mini-mental state. A practical method for grading the cognitive state of patients for clinician // J. Psychiatr.Res. – 1975. – № 12. – P. 189–190.
266. Foong J., Rozewicz I., Chong W.K. et al. A comparision of neuropsychological deficits in primary and secondary progressive MS // J Neurol. – 2000. – V. 247. – № 1. – P. 97–101.
267. Foss T., Eide P. K., Finset A. Intracranial pressure parameters in INPH patients with or without improvement of cognitive function after shunt treatment // Dement Geriatr Cogn Disord. – 2007. – V. 23. – № 1. – P. 47–54.
268. Fraga H. G., Figueiredo E., Fraga A. Cognitive function and dementia risk in hypertensive patients // Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 308–309.
269. Fuchs G. A., Gemende I., Herting B. et al. Dementia in idiopathic Parkinsons Syndrome // J.Neurol. – 2004. – V. 251 (Suppl 6). – P. VI/28–VI/32.
270. Galvin J. E. Cognitive change in Parkinson disease // Alzheimer Dis Assoc Disord. – 2006. – V. 20. – № 4. – P. 302–310.
271. Genovesti G., Paolini P., Marcellini L. Relationship between autoimmune thyroid disease rand Alzheimers disease // Panminerva. – 1996. – V. 38. – № 1. – P. 61–63.
272. Giacobini E. Future of cholinergic therapy in dementia // Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 12.
273. Glad S. B., Nyland H., Nortvedt M. et al. Patients with benign multiple sclerosis have reduced quality of life // Eur. J. Neurol. – 2004. – V. 11 (Suppl 2). – P. 262.
274. Godefroy O., Stuss D. Dysexecutive syndromes // The behavioral and cognitive neurology of stroke/ ed. Godefroy O.G., Bogousslavsky J. – Cambridge: University press, 2007. – P. 369–406.
275. Goldberg A. L. On prions, proteasomes, and mad cows. disease // N Engl J Med. – 2007. – V. 357. – № 11. – P. 1150–1152.
276. Goldberg R. B., Holman R., Drucker D. J. Management of type 2 diabetes // N Engl J Med. – 2008. – V. 358. – № 3. – P. 293–297.
277. Gorospe E. C., Dave J. K. The risk of dementia with increased body mass index // Age and Ageing. – 2007. – V. 36. – № 1. – P. 23–29.
278. De Graaf-Peters V. B., Hadders-Algra M. Ontogeny of the human central nervous system: what is happening when? // Early Hum Dev. – 2006 – V. 82. – № 4. – P. 57–66.
279. Graber P., Rosenmund A., Probst A. et al. Multiple sclerosis-like illness in early HIV infection // AIDS. – 2000. – V. 14. – № 11. – P. 2411–2413.
280. Growdon J. H. Biomarkers of neurodegenerative disease // Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 109.
281. Green R. C. Diagnosis and management of Alzheimers disease and other dementias. – NY.: Professional communications, Inc, 2005. – 256 p.
282. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults // N Engl J Med. – 2005. – V. 352. – № 1. – P. 48–62.
283. Gupta R., Solanki R. K., Pathak V. Blood pressure is associated with cognitive impairment in young hypertensives // World J. Biol. Psychiatry. – 2007. – V. 8. – № 1. – P. 1–8.
284. Hampel H., Burger K., Teipel S. J. et al. Core candidate neurochemical and imaging biomarkers of Alzheimers disease // Alzheimers dementia. – 2008. – V. 4. – № 1. – P. 38–48.
285. Hayley S., Anisman H. Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates // Curr. Pharm. Des. – 2005. – V. 11. – № 8. – P. 947–962.
